Latest investigations into retatruptide peptide highlight significant possibility for managing weight and non-insulin dependent disease. The compound, a dual activator of GLP-1 and GIP receptor, looks to present enhanced weight reduction and glucose control compared existing treatments. Additional clinical trials are required to completely assess i